Table 1.
Clinical and demographic characteristics of patients
| Characteristics | SVS (n = 76) | AVS (n = 74) | χ2/t, P |
|---|---|---|---|
| Age (years) | 48.9 ± 8.1 | 47.6 ± 7.9 | 1.016, 0.311 |
| Gender (male/female) | 39/37 | 40/34 | 0.113, 0.737 |
| Smoking | 27 | 20 | 1.259, 0.262 |
| Drinking | 19 | 21 | 0.219, 0.640 |
| Pre-existing diseases | |||
| Coronary artery disease | 29 | 25 | 0.311, 0.577 |
| Hypertension | 38 | 36 | 0.027, 0.869 |
| Diabetes mellitus | 21 | 22 | 0.081, 0.776 |
| Hyperlipidaemia | 23 | 25 | 0.214, 0.644 |
| Current medications | |||
| Pioglitazone | 9 | 6 | 0.581, 0.446 |
| Ca-CB | 23 | 21 | 0.064, 0.800 |
| β-blocker | 30 | 33 | 0.404, 0.525 |
| EPA | 15 | 13 | 0.116, 0.733 |
| Nitrates | 17 | 11 | 1.390, 0.238 |
| Aspirin | 48 | 47 | 0.002, 0.964 |
| Clopidogrel | 8 | 15 | 2.742, 0.098 |
| Insulin | 7 | 11 | 1.135, 0.287 |
| ACEI/ARB | 12 | 9 | 0.430, 0.522 |
| RASB | 34 | 35 | 0.099, 0.753 |
Notes: RASB, Renin-angiotensin system blocker; Ca-CB, calcium channel blockers; ARB, denotes angiotensin II receptor blocker; ACE-I, angiotensin-converting enzyme inhibitor; EPA, eicosapentaenoic acid.